Naegis Pharmaceuticals Inc. (“Naegis”) a life sciences company focused on inflammation and ophthalmology, today announced the closing of a financing. Over the next 12 months, the funding will support advancement of a patented lead compound through to approval of a U.S. FDA Investigational New Drug (IND) application to enter a Phase 2 clinical trial.

read more